Document is current

Documents that mention this clinical trial

116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
https://doi.org/10.1007/s11523-021-00809-2

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601

480 Investigating genetic predisposition to immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-sitc2024.0480

Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612

375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375

Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
https://doi.org/10.1007/s12325-019-01018-0

6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006

Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-008480

Documents that mention this clinical trial

Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models
https://doi.org/10.1136/jitc-2025-013158

Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia
https://doi.org/10.1136/bmjopen-2023-076898

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
https://doi.org/10.1200/jco.21.02508

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048
https://doi.org/10.1007/s10147-024-02632-x

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
https://doi.org/10.1007/s10147-022-02233-6

Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives
https://doi.org/10.1136/jim-2018-000743

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664

Documents that mention this clinical trial

116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8

44 Early kinetics of circulating tumor HPV-16 and HPV-18 DNA are associated with survival in patients with HPV-associated cancers treated with dual blockade of PD-L1 and TGF-β
https://doi.org/10.1136/jitc-2025-sitc2025.0044

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
https://doi.org/10.1136/jitc-2021-003113

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601

Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612

375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375

6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006